Results 1 to 10 of about 8,864 (209)

Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling [PDF]

EJNMMI Physics, 2023
Background Prediction of [177Lu]Lu-HA-DOTATATE kidney and tumor uptake based on diagnostic [68Ga]Ga-HA-DOTATATE imaging would be a crucial step for precision dosing of [177Lu]Lu-HA-DOTATATE.
Marcel P M Stokkel, Jos Beijnen, Alwin D R Huitema   +2 more
exaly   +4 more sources

177Lu-DOTATATE therapy in metastatic/ inoperable pheochromocytoma-paraganglioma

Endocrine Connections, 2020
Introduction: 177Lu-DOTATATE-based peptide receptor radionuclide therapy (PRRT) is a promising therapy for metastatic and/or inoperable pheochromocytoma and paraganglioma (PPGL).
Sanjeet Kumar Jaiswal, Vijaya Sarathi, Saba Samad Memon, Robin Garg, Gaurav Malhotra, Priyanka Verma, Ravikumar Shah, Manjeet Kaur Sehemby, Virendra A Patil, Swati Jadhav, Anurag Ranjan Lila, Nalini S Shah, Tushar R Bandgar   +12 more
doaj   +3 more sources

Initial clinical evaluation of indigenous 90Y-DOTATATE in sequential duo-PRRT approach (177Lu-DOTATATE and 90Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability,90Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects

World Journal of Nuclear Medicine, 2021
177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) alone has lesser potential in the clinical setting of neuroendocrine tumor (NET) with large bulky disease and nonhomogeneous somatostatin receptors (SSTR) distribution, owing to lower energy ...
Rahul Parghane, Arpit Mitra, Trupti Bannore, Sutapa Rakshit, Sharmila Banerjee, Sandip Basu   +5 more
doaj   +1 more source

Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma

Frontiers in Endocrinology, 2021
BackgroundLutetium 177 (177Lu) - DOTATATE is a form of peptide receptor radionuclide therapy (PRRT) utilized in the treatment of neuroendocrine tumors. Data on 177Lu-DOTATATE-induced thyroid dysfunction is limited.Case DescriptionA 29-year-old male with ...
Sriram Gubbi, Mohammad Al-Jundi, Jaydira Del Rivero, Abhishek Jha, Marianne Knue, Joy Zou, Baris Turkbey, Jorge Amilcar Carrasquillo, Emily Lin, Karel Pacak, Joanna Klubo-Gwiezdzinska, Frank I-Kai Lin   +11 more
doaj   +1 more source

A method to prevail false positive responses due to excess cations and viscous nature of Radiopharmaceuticals in Limulus Amebocyte Lysate Gel Clot test [PDF]

Asia Oceania Journal of Nuclear Medicine and Biology, 2022
Objective(s): Bacterial endotoxin test (BET) for detection and quantification of endotoxin in radiopharmaceuticals (RPs), used for therapy or diagnosis, is prerequisite to administration in patients.
Arpit Mitra, Sangita Lad, Sudeep Sahu, Savita Kulkarni   +3 more
doaj   +1 more source

177Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience

JCO Global Oncology, 2021
PURPOSETo compare the efficacy and safety of 177Lu-DOTATATE plus radiosensitizing capecitabine and octreotide long-acting release (LAR) as first-line systemic therapy in advanced well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Swayamjeet Satapathy, Bhagwant R. Mittal, Ashwani Sood, Apurva Sood, Rakesh Kapoor, Rajesh Gupta, Divya Khosla   +6 more
doaj   +1 more source

Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland

BMC Cancer, 2021
Background Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent a heterogenous group of tumors. Findings from the phase III NETTER-1 trial showed that treatment of unresectable/metastatic progressive gastrointestinal (GI) NETs with 177Lu ...
J. Smith-Palmer, O. R. Leeuwenkamp, J. Virk, N. Reed   +3 more
doaj   +1 more source

In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy. [PDF]

PLoS ONE, 2017
BACKGROUND:Absorbed doses for α-emitters are different from those for β-emitters, as the high linear energy transfer (LET) nature of α-particles results in a very dense energy deposition over a relatively short path length near the point of emission ...
Ho Sze Chan, Erik de Blois, Alfred Morgenstern, Frank Bruchertseifer, Marion de Jong, Wouter Breeman, Mark Konijnenberg   +6 more
doaj   +1 more source

Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With 177Lu-DOTATATE: A Case Report

Frontiers in Endocrinology, 2021
IntroductionPrimary cardiac paragangliomas are rare tumors. Metastatic disease is even rarer. Surgical management is technically challenging, and sometimes even impossible.
Alexis Huot Daneault, Mélanie Desaulniers, Jean-Mathieu Beauregard, Alexis Beaulieu, Frédéric Arsenault, Geneviève April, Éric Turcotte, François-Alexandre Buteau   +7 more
doaj   +1 more source

Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors

Frontiers in Endocrinology, 2021
Peptide receptor radionuclide therapy (PRRT) is an established treatment in advanced neuroendocrine tumors (NETs), which overexpressed somatostatin receptors. However, after progression there are a limited number of available treatments. We want to share
Elena María Vida Navas, Alberto Martínez Lorca, Aintzane Sancho Gutiérrez, Lucia Sanz Gómez, Teresa Navarro Martínez, Enrique Grande Pulido, Alfredo Carrato Mena, Pablo Gajate Borau   +7 more
doaj   +1 more source